A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)
A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)
The purpose of the study is to evaluate the efficacy of bedaquiline (BDQ) compared with
 rifamycin when administered as part of a treatment regimen with clarithromycin (CAM) and
 ethambutol (EB) in adult participants with treatment-refractory Mycobacterium avium
 complex-lung disease (MAC-LD) at Week 24 for microbiological assessment in mycobacteria
 growth indicator tube (MGIT).
Inclusion Criteria:

 -  Has body weight greater than or equal to (>=) 40 kilograms (kg) at screening and on
 Day 1

 -  Has radiological evidence consistent with nontuberculous mycobacterial lung disease
 (NTM-LD) based on a chest Computed Tomography (CT) scan taken within 6 months prior to
 screening or at screening

 -  Has at least 2 positive sputum cultures of Mycobacterium avium complex (MAC) (sputum
 cultures to be taken at least 4 weeks apart): one obtained within 12 months prior to
 screening, which was documented while being treated for Mycobacterium avium complex
 lung disease (MAC-LD) for a total of at least 6 months and no longer than 24 months;
 and one at screening (by central microbiology laboratory)

 -  Received at least 6 months and no more than 24 months of consecutive MAC-LD treatment
 (at least 2 antibiotics for MAC, including a macrolide), that is either ongoing or has
 stopped within 12 months prior to screening

 -  No presence of cognitive dysfunction that would impact the completion of the patient
 reported outcome (PRO) assessments

 Exclusion Criteria:

 -  Had previous exposure to bedaquiline (BDQ)

 -  Has active Tuberculosis (TB) disease

 -  Has cystic fibrosis, medically unstable respiratory disease (for example, chronic
 obstructive pulmonary disease, bronchiectasis, asthma)

 -  Has one or more cavities >=2 centimeter (cm) in diameter on a chest CT scan taken
 within 6 months prior to screening or at screening

 -  Treatment already includes an injectable/inhaled aminoglycoside within 3 months prior
 to screening or the investigator deems the participant to be a candidate for an
 aminoglycoside at screening